Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Metastatic Solid Tumors 2

Interventions

pembrolizumab 75Injections 67Carboplatin 38Pemetrexed 29Cisplatin 29Nivolumab 27Specimen Handling 24Interviews as Topic 24Cyclophosphamide 24atezolizumab 21tislelizumab 20Bevacizumab 20Paclitaxel 19Standard of Care 16Practice Guidelines as Topic 16fludarabine 15Docetaxel 15toripalimab 14Ipilimumab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Infusions, Intravenous × Other solid neoplasm × 1 year × Clear all
NCT07108114 2026-02-23

SLV-324 Treatment of Metastatic Solid Tumors

Solve Therapeutics

Phase 1 Recruiting
70 enrolled
Other solid neoplasm

Metastatic Solid Tumors

NCT07272590 2025-12-09

Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
290 enrolled
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡